• Tonix Pharmaceuticals highlighted the commercial rollout of fibromyalgia drug TONMYA, launched Nov. 17, 2025; FDA clearance cited for Aug. 2025.
• Reported TONMYA net sales of USD 3.7 million in 1Q26; USD 5.1 million from Nov. 17, 2025 to Mar. 31, 2026.
• Commercial metrics showed more than 2,600 unique prescribers from Nov. 17, 2025 to Apr. 17, 2026; about 11,016 prescriptions through May 1, 2026.
• Cash and cash equivalents totaled about USD 185.5 million as of March 31, 2026; no debt; runway expected into early Q2 2027.
• Pipeline focus included TNX-4800 Lyme disease prevention study planned for 1H27; TNX-1500 transplant rejection Phase 2 planned mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.